Edison's EPI-743 the first to show disease reversal promise in Leigh's
This article was originally published in Scrip
All 10 children in a Phase IIa clinical trial experienced a reversal in the progression of Leigh syndrome (subacute necrotising encephalomyelopathy) during treatment with Edison Pharmaceuticals' EPI-743, according to the first-ever published report of disease reversal for the progressive and usually fatal neuromuscular disorder, which primarily is diagnosed in infants and children.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.